Life sciences talent and strategic consultancy, RBW Consulting, has announced the appointment of Dr Mel Walker as non-executive board director.
Mel has over 20 years of healthcare leadership experience in the UK, European and Global markets and has held leadership roles in two of the top ten global pharmaceutical companies. He is currently managing director of Biopharma Futures, an advisory board member at PharmaCCX and NDA Group, strategic advisor at Eleusis and an advisory council member at TOPRA.
The perspective Mel will bring from the client-side will add further weight to RBW’s extensive life science market expertise. Mel will also support the development of a new consultancy offering from RBW, focused on providing clients who are expanding into Europe with an end-to-end early commercial consulting & search service.
“We’re delighted to welcome Mel to the board of directors,” says Emma Thorp, chief growth officer at RBW. “His specialist knowledge and insight will enable us to seamlessly expand our offering as we enter into this exciting period of growth at RBW. With Mel on board, our clients will have access to a unique and comprehensive consulting service at key stages of their commercial planning.”
Mel joins the team following the recent launch of a brand-new look for the company. The new branding rearticulates RBW’s founding operating ethos and the core values that drive everything it does through a clearly expressed narrative grounded in Human IntelligenceTM and purpose, in addition to a complete change in company branding.
Commenting on his appointment, Mel Walker said, “I am delighted to be supporting the RBW team at such an exciting time for the company and wider industry. I am passionate about ensuring that patients have access to innovative therapies and delivering on this mission fundamentally relies on recruiting and developing talent. I joined the RBW team because of their people focus and core values and I look forward to seeing what we can achieve together.”
